
ALT Johnson & Johnson. 2026 Q3, $762M portfolio. Top 6 of 15 holdings, 92.3% of the portfolio: 1. PTGX (Protagonist Therapeutics), 45.3%; 2. NBTX (Nanobiotix), 23.0%; 3. MGTX (MeiraGTx), 9.6%; 4. RAPP (Rapport Therapeutics), 7.9%; 5. CTNM (Contineum Therapeutics), 3.5%; 6. CBRS (Cerebras Systems), 3.0%. SEC 13F filing, not investment advice. followthefilings.com.

ALT Greenhaven Associates. 2026 Q3, $8B portfolio. Bars: share of the portfolio traded since 2026 Q2. Bought: LEN (Lennar), Added, 11.8% to 13.4%; BDX (Becton Dickinson), Added, 9.9% to 13.3%; BBWI (Bath & Body Works), New, now 0.0%. Sold: ACN (Accenture), Exited, was 4.9%; LEA (Lear), Trimmed, 2.3% to 1.2%; EPAM (EPAM Systems), Exited, was 0.5%. SEC 13F filing, not investment advice. followthefilings.com.

ALT Old Republic International. 2026 Q3, $2.2B portfolio. Bars: share of the portfolio traded since 2026 Q2. Bought: SPYM (SPDR Series Trust), New, now 0.3%. Sold: MSCI (MSC Industrial Direct), Trimmed, 1.8% to 0.2%; ETN (Eaton), Trimmed, 3.2% to 2.1%; CAT (Caterpillar), Trimmed, 3.4% to 1.7%; CMI (Cummins), Trimmed, 3.2% to 1.7%; VLO (Valero Energy), Trimmed, 1.9% to 2.9%. SEC 13F filing, not investment advice. followthefilings.com.
